Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

“Researchers will use gamma scintigraphy to evaluate the transit of Brilacidin to the colon. Safety and tolerability are, of course, top priority, but targeted delivery to the intended site is not far behind in importance.”

This should be black and white unlike some of the other data from previous trials. IMO - all of the B data across all indications have a level of positive results and so I do believe the properties of B are valuable. B-OM good results. B-UP enema great results and partnered. B-absssi - great results and not lucrative enough for BP.

So if B can all of a sudden continue to be safe and effective but now in an ORAL form and deliver deep into the GI tract for UC, and Crohn’s.
I believe my long term friends........we have just hit pay dirt.

Well know soon enough.